Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy
-
Abstract Number: 444
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
-
Abstract Number: 446
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
-
Abstract Number: 447
Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study
-
Abstract Number: 448
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
-
Abstract Number: 449
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
-
Abstract Number: 450
Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
-
Abstract Number: 451
Pilot Study of Stimulation of the Cholinergic Anti-Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis
-
Abstract Number: 452
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
-
Abstract Number: 453
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
-
Abstract Number: 454
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
-
Abstract Number: 455
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
-
Abstract Number: 457
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
-
Abstract Number: 459
Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
-
Abstract Number: 460
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
-
Abstract Number: 461
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
-
Abstract Number: 462
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
-
Abstract Number: 463
Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
-
Abstract Number: 464
Rituximab for Treatment of Rheumatoid Arthritis: Treatment Effectiveness in the Corrona Database
-
Abstract Number: 465
The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Treatment of Early Rheumatoid Arthritis
-
Abstract Number: 466
Synovialitis Plus Articular Cartilage Monitoring Via Magnetic Resonance Imaging and Ultrasound Under Tocilizumab Therapy in Patients with Rheumatoid Arthritis
-
Abstract Number: 468
Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 24 Months
-
Abstract Number: 469
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
-
Abstract Number: 470
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
-
Abstract Number: 471
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
-
Abstract Number: 472
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
-
Abstract Number: 474
Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses
-
Abstract Number: 475
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
-
Abstract Number: 476
Effects of Vitamin D Repletion and Maintenance Therapy On Clinical Indicators of Disease Activity in Rheumatoid Arthritis
-
Abstract Number: 477
Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis
-
Abstract Number: 478
Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
-
Abstract Number: 479
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
-
Abstract Number: 480
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
-
Abstract Number: 481
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
-
Abstract Number: 482
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
-
Abstract Number: 483
An Evaluation of Literature On Discontinuation Rates of Biologics in Rheumatoid Arthritis
-
Abstract Number: 484
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
-
Abstract Number: 485
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
-
Abstract Number: 486
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
-
Abstract Number: 487
Functional Disability in Early Rheumatoid Arthritis – Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies
-
Abstract Number: 488
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
-
Abstract Number: 489
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
-
Abstract Number: 491
Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population
-
Abstract Number: 492
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
-
Abstract Number: 493
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
-
Abstract Number: 494
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
-
Abstract Number: 495
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
-
Abstract Number: 496
Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data 3 Outcomes: The Canadian Experience
-
Abstract Number: 497
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
-
Abstract Number: 498
LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
-
Abstract Number: 499
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
-
Abstract Number: 500
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
-
Abstract Number: 501
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
-
Abstract Number: 502
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
-
Abstract Number: 503
Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
-
Abstract Number: 1271
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
-
Abstract Number: 1273
Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
-
Abstract Number: 1275
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
-
Abstract Number: 1276
Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab
-
Abstract Number: 1278
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
-
Abstract Number: 1279
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
-
Abstract Number: 1281
IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
-
Abstract Number: 1282
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
-
Abstract Number: 1283
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
-
Abstract Number: 1284
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
-
Abstract Number: 1285
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
-
Abstract Number: 1286
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
-
Abstract Number: 1287
Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
-
Abstract Number: 1288
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
-
Abstract Number: 1289
Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
-
Abstract Number: 1290
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
-
Abstract Number: 1291
A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX)
-
Abstract Number: 1293
Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
-
Abstract Number: 1295
Effectiveness and Tolerability of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients Switched From Intravenous Tocilizumab: Results From the Extension Period of the Musashi Study
-
Abstract Number: 1298
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
-
Abstract Number: 1299
Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study
-
Abstract Number: 1300
Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
-
Abstract Number: 1302
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
-
Abstract Number: 1303
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
-
Abstract Number: 1304
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
-
Abstract Number: 1305
Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry
-
Abstract Number: 1306
How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
-
Abstract Number: 1307
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
-
Abstract Number: 1308
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
-
Abstract Number: 1309
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
-
Abstract Number: 1310
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
-
Abstract Number: 1311
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
-
Abstract Number: 1313
Tolerance of Rituximab in Patients with a History of Cancer : Data From the Registry Air
-
Abstract Number: 1314
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
-
Abstract Number: 1315
Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
-
Abstract Number: 1316
Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
-
Abstract Number: 1317
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
-
Abstract Number: 1319
Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
-
Abstract Number: 1321
C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
-
Abstract Number: 1322
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
-
Abstract Number: 1323
Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 24-Week Study in a United States Population
-
Abstract Number: 1325
Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
-
Abstract Number: 1326
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
-
Abstract Number: 1327
Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea
-
Abstract Number: 1329
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
-
Abstract Number: 1330
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
-
Abstract Number: 1331
Once Daily High Dose Regimens of GLPG0634 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK1 but Not JAK2
-
Abstract Number: 1332
The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA
-
Abstract Number: 1333
The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)
-
Abstract Number: 1334
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
-
Abstract Number: 1335
Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy
-
Abstract Number: 1336
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
-
Abstract Number: 1338
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
-
Abstract Number: 1341
Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients
-
Abstract Number: 2149
Atsttrin-â, an Engineered Protein Derived From Progranulin Growth Factor, Binds to TNF Receptors and Exhibits Potent Anti-Inflammatory Activity in Mice
-
Abstract Number: 2150
Action of Tofacitinib Via Human Dendritic Cells
-
Abstract Number: 2152
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
-
Abstract Number: 2154
Regulation of Folate Pathway Related Genes in Methotrexate naïve and Methotrexate Treated Patients with Rheumatoid Arthritis
-
Abstract Number: 2155
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
-
Abstract Number: 2156
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
-
Abstract Number: 2157
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
-
Abstract Number: 2158
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
-
Abstract Number: 2160
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
-
Abstract Number: 2161
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
-
Abstract Number: 2164
Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages
-
Abstract Number: 2166
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
-
Abstract Number: 2167
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
-
Abstract Number: 2168
Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry
-
Abstract Number: 2169
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
-
Abstract Number: 2170
Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis – A Systematic Literature Review and Meta-Analysis
-
Abstract Number: 2171
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis